Drug Trial Radar · NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
433
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Conditions
- Advanced Solid Tumor
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive Malignant Neoplasm of Breast
- HER2-negative Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
BGB-43395Drug
Planned doses administered orally.
FulvestrantDrug
Standard dose administered via intramuscular injection.
LetrozoleDrug
Standard dose administered orally as a tablet.
ElacestrantDrug
Standard dose administered orally as a tablet.
Anti-Diarrheal AgentDrug
Administered orally as a tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 60 months
- Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395Time frame: Up to approximately 60 months
- Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395Time frame: Up to approximately 60 months
- Phase 1b: Objective Response Rate (ORR)Time frame: Up to approximately 60 months
Locations
61 sites in 11 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute (Scri) At Health One
Denver, Colorado · Recruiting
Florida Cancer Specialists and Research Institute
Lake Mary, Florida · Completed
Karmanos Cancer Institute
Detroit, Michigan · Completed
Duke Cancer Center
Durham, North Carolina · Recruiting
James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Scri Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Next Oncology Dallas
Irving, Texas · Recruiting
Next Oncology
San Antonio, Texas · Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia · Recruiting
Southern Highlands Private Hospital
Bowral, New South Wales, Australia · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
Macquarie University
North Ryde, New South Wales, Australia · Recruiting
Townsville University Hospital
Douglas, Queensland, Australia · Recruiting
Genesiscare St Andrews
Adelaide, South Australia, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Completed
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Fundacao Pio Xii Hospital de Amor de Barretos
Barretos, Brazil · Recruiting
Hospital Sirio Libanes Brasilia
Brasília, Brazil · Recruiting
Fundacao Universidade de Caxias Do Sul
Caxias do Sul, Brazil · Recruiting
Centro de Pesquisas Oncologicas Cepon
Florianópolis, Brazil · Recruiting
Liga Norte Riograndene Contra O Cancer
Natal, Brazil · Recruiting
Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia
Porto Algre, Brazil · Recruiting
Instituto Nacional de Cancer
Rio de Janeiro, Brazil · Recruiting
Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael
Salvador, Brazil · Recruiting
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
São Paulo, Brazil · Recruiting
Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria
São Paulo, Brazil · Recruiting
Hospital Israelita Albert Einstein
São Paulo, Brazil · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China · Recruiting
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China · Recruiting
Fudan University Shanghai Cancer Centerpudong
Shanghai, Shanghai Municipality, China · Recruiting
Centre de Lutte Contre Le Cancer Institut Bergonie
Bordeaux, France · Recruiting
Centre Francois Baclesse
Caen, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
Institut Curie
Paris, France · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.